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Abstract
Background: One of the main challenges for drug evaluation in rare diseases is the often heterogeneous course
of these diseases. Traditional outcome measures may not be applicable for all patients, when they are in different
stages of their disease. For instance, in Duchenne Muscular Dystrophy, the Six Minute Walk Test is often used to
evaluate potential new treatments, whereas this outcome is irrelevant for patients who are already in a wheelchair.
A measurement instrument such as Goal Attainment Scaling (GAS) can evaluate the effect of an intervention on
an individual basis, and may be able to include patients even when they are in different stages of their disease. It
allows patients to set individual goals, together with their treating professional. However, the validity of GAS as a
measurement instrument in drug studies has never been systematically reviewed. Therefore, we have performed a
systematic review to answer two questions: 1. Has GAS been used as a measurement instrument in drug studies?
2: What is known of the validity, responsiveness and inter- and intra-rater reliability of GAS, particularly in drug
trials?
Methods: We set up a sensitive search that yielded 3818 abstracts. After careful screening, data-extraction was
executed for 58 selected articles.
Results: Of the 58 selected articles, 38 articles described drug studies where GAS was used as an outcome
measure, and 20 articles described measurement properties of GAS in other settings. The results show that
validity, responsiveness and reliability of GAS in drug studies have hardly been investigated. The quality of the
reporting of validity in studies in which GAS was used to evaluate a non-drug intervention also leaves much
room for improvement.
Conclusions: We conclude that there is insufficient information to assess the validity of GAS, due to the poor
quality of the validity studies. Therefore, we think that GAS needs further validation in drug studies, especially
since GAS can be a potential solution when a small heterogeneous patient group is all there is to test a
promising new drug.
Trial registration: The protocol has been registered in the PROSPERO international prospective register for
systematic reviews, with registration number CRD42014010619. http://www.crd.york.ac.uk/PROSPERO/display_
record.asp?ID=CRD42014010619.
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Background
One of the main challenges for drug evaluation in rare
diseases is the heterogeneous course of these diseases.
When a disease course differs from patient to patient,
traditional outcome measures may not be applicable for
all patients of a certain disease. Trial designs are often
limited to patients for whom the outcome measure is
relevant, whereas the underlying disease mechanism
may be similar in a larger group. This increases the
problem of small numbers that already challenges rare
disease research.
For example, in Duchenne muscular dystrophy (DMD),
new drug trials until recently often used the 6-min Walk
Test (6MWT) as an outcome measure. The 6MWT has
been validated as a reliable and feasible outcome measure,
and has been recommended as the primary outcome
measure in ambulatory DMD patients [1, 2]. However,
although the 6MWT may be a relevant outcome measure
for boys who are not (yet) depending on a wheelchair, it is
obviously irrelevant for, usually somewhat older, boys who
are. This problem in DMD research has been picked up
by patient representatives and researchers from all over
the world [3].
As the DMD example shows, existing measurement
instruments use an outcome that is not relevant for all
patients, or may not be responsive enough to measure
the effect of an intervention in a rare disease. However,
the development of disease-specific and patient-relevant
outcome measures is hampered by the small number
and heterogeneity of patients with a particular rare dis-
ease. In their handbook “Measurement in Medicine” De
Vet et al. [4] recommend a minimum number of 50 pa-
tients for validation studies.
A measurement instrument that can evaluate the ef-
fect of an intervention on an individual basis may help
overcome the problem of small, heterogeneous popula-
tions. The importance of patient reported outcome mea-
sures is widely recognized by pharmaceutical companies
and clinical researchers as well as regulators and govern-
ment agencies such as FDA and NIH [5].
Goal Attainment Scaling (GAS) is a measurement in-
strument that is intended for individual evaluation of an
intervention. It allows patients to set individual goals, to-
gether with their treating professional. The number of
goals and the content of these goals may differ per pa-
tient, but the attainment of the goals is measured in a
standardized way. This makes a standardized evaluation
of an intervention possible, even when the patients are
all in a different stage of their disease.
Goal Attainment Scaling was first introduced in 1968,
by Kiresuk and Sherman [6], originally for the evaluation
of mental health services. It contains a variable number
of self-defined goals and very explicit descriptions of five
possible levels of goal attainment that are formulated
before the intervention, usually in consultation between
the patient and the clinician. In the original definition,
the levels are each quantified in a 5-point scale that
ranges from −2 to +2, where −2 = the most unfavorable
treatment outcome thought likely, −1 = less than ex-
pected level of treatment success, 0 = expected level of
treatment success, +1 =more than expected success with
treatment, and +2 = best conceivable success with treat-
ment. For each goal the expected level of treatment
success and at least two other levels need to be
described in such a specific way that an independent
observer can assess the outcome.
There is no maximum number of goals that can be
set. Each goal can be assigned a weight, according to its
importance to patient and/or clinician. From the scores
reached after the intervention, a composite goal attain-
ment score is computed using the following formula:









where T is the composite score, wi is the weight assigned
to the goali, xi is the original score for goali ranging from
−2 to +2, and ρ is the estimated correlation between goal
scores. According to Kiresuk and Sherman, it is safe to
assume that the correlation between the goal scores is
constant, and can be set at 0.3. The T-score has a mean
of 50 and a standard deviation of 10, under the assump-
tions as proposed by Kiresuk and Sherman [6].
Besides mental health and non-medical fields such as
education and social service applications [7], GAS is re-
portedly used in a few specific medical research areas,
such as rehabilitation [8–12] and geriatrics [13–15].
However, the validity of GAS as a measurement instru-
ment in drug studies has never been systematically
reviewed. To evaluate the usefulness of GAS in drug
studies, we formulated the following three research
questions:
1. Has Goal Attainment Scaling been used as a
measurement instrument in drug studies?
2. What (drug) interventions were evaluated by studies
using GAS?
3. What is known of the validity, responsiveness and
inter- and intra-rater reliability of Goal Attainment
Scaling in general, and in particular in drug trials?
In this study, we follow the COSMIN guidelines, which
are the generally used and accepted standards for measure-
ment properties evaluation [16]. This checklist contains
standards for evaluating the methodological quality of
studies on the measurement properties of health measure-
ment instruments. According to the COSMIN guidelines,
Gaasterland et al. BMC Medical Research Methodology  (2016) 16:99 Page 2 of 22
a health status measurement instrument can be used when
its validity, reliability and responsiveness, have been tested
and considered adequate. We considered GAS useful when
the validity, reliability and responsiveness have been de-
scribed, tested and found acceptable according to these
guidelines.
Methods
We conducted a systematic review, according to the
PRISMA guidelines [17].
We set up a sensitive search in Medline, PsychInfo
and Embase. We searched for literature from 1968, the
year when GAS was introduced by Kiresuk and Sherman
[6], to May 1st, 2015. For the full search strategy, see
Additional file 1. Reference lists of relevant review arti-
cles were screened for additional papers.
Papers were included in which:
1. Goal Attainment Scaling met the following criteria:
– One or more individual goals were established by
the patient or by one or more researchers or
practitioners, either with or without input of the
patient, prior to the intervention. The goals did
not have to be devised by the patient/researcher,
as long as the goals were individually chosen per
patient.
– The scale had to consist of at least three points
(e.g. more than just goal attained – goal not
attained). At least 2 points on the scale were
described precisely and objectively, so that an
independent observer would be able to determine
whether the patient performs above or below that
point.
2. The study was either a trial in which drugs are
evaluated, or a study of any design in which
psychometric properties of GAS were evaluated.
3. The outcome measure was the attainment of goals
that had been established before the onset of the
intervention.
4. The goals had been set up individually, i.e. per
patient.
Excluded were:
1. Trials using an outcome measure called Goal
Attainment Scaling, when the outcome measure did
not meet our definition of GAS.
2. Studies in which goal setting was used as an
intervention rather than outcome measurement.
3. Reviews or narratives.
4. Conference abstracts.
5. Papers published in languages other than English,
French, Dutch, German or Spanish.
6. Papers published before 1968.
The selection of articles and data-extraction were per-
formed in pairs of two independent reviewers. Disagree-
ments were discussed until consensus was reached; if
necessary a third reviewer acted as a referee. A standard-
ized data-extraction form was used (see Additional file 2).
We divided the included studies into two categories, i.e.
drug studies, and non-drug studies in which the meas-
urement properties of GAS were investigated.
We extracted information about the following meas-
urement properties, defined according to the COSMIN
guidelines [18]: Inter-rater reliability, intra-rater reliabil-
ity, face validity, content validity, construct validity, and
responsiveness. For the full definitions of the measure-
ment properties, see Table 1. We used the quality cri-
teria as proposed by Terwee et al. [19] to evaluate the
measurement properties, as also displayed in Table 1.
We chose to limit the evaluation of the quality of the
measurement properties to the criteria as proposed by
Terwee et al., instead of using the full COSMIN guide-
lines, because the COSMIN guidelines are very detailed,
and many details are not relevant as these aspects can-
not be evaluated for GAS, e.g. internal consistency,
measurement error, criterion validity.
Results
The search yielded 3007, 1413, and 1039 abstracts from
Medline, Embase and PsychInfo, respectively. After elim-
inating duplicates, a total of 3818 abstracts remained for
screening. In the screening phase, we excluded 3511 arti-
cles based on title and abstract, and 249 articles based
on the full text. Data-extraction was executed for the
remaining 58 articles (see Fig. 1). Of these 58 articles, 38
articles described drug studies in which GAS was used
as an outcome measure, and 20 articles described meas-
urement properties of GAS in other settings (Fig. 2).
In Table 2 the characteristics of the articles are pre-
sented. Most studies are trials in patients with cerebral
palsy or patients with spasticity due to other causes,
such as acquired brain trauma or stroke (28 studies).
Also, many studies focussed on the geriatric population
(15 studies). There were also some studies on autism
(three studies), or neurological disorders such as MS
(two studies). The remaining studies covered research
areas such as family problems, goal setting in adolescent
students or behaviour and psychiatric problems.
Most drug studies evaluated an intervention with
botulinum toxin (25 studies), mainly in patients with
cerebral palsy and spasticity. Baclofen was also evaluated
in children with spasticity (three studies). Other drugs
that were evaluated, were galantamine (three studies),
donepezil for Alzheimer’s Disease (two studies), fluvox-
amine, trihexyphenidil, memantine, a phenol nerve
block, and linopirdine (one study each).
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An overview of the reported measurement properties
of GAS in the 38 drug studies and the 20 non-drug stud-
ies is presented in Tables 3 and 4, respectively.
Face validity
As is shown in Tables 3 and 4, face validity is reported
in one article [20]. This is a drug study that evaluated
Table 1 COSMIN definitions [49] of the evaluated measurement properties, and their quality criteria [19]
Measurement
Property
COSMIN definition Quality criteria (+ equals good to very good quality, +/−
equals intermediate quality and – equals poor quality)
Inter-rater
reliability
The extent to which scores for patients who have not changed
are the same for repeated measurement by different persons
on the same occasion
+ ICCa or weighted Kappa ≥0.7
+/− Unclear design or method
- ICC or weighted Kappa ≤0.7
Intra-rater
reliability
The extent to which scores for patients who have not changed
are the same for repeated measurement by the same persons
(i.e. raters or responders) on different occasions
+ ICC or weighted Kappa ≥0.7
+/− Unclear design or method
- ICC or weighted Kappa ≤0.7
Face validity The degree to which the items of a Health Related-Patient
Reported Outcome (HR-PRO) instrument indeed look as though
they are an adequate reflection of the construct to be measured
+ A clear description is provided of the measurement aim,
target population, the concepts that are measured, and the
item selection and target population were involved in item
selection
+/− A clear description of these aspects is lacking, or only
target population involved, or doubtful design or method
- No target population involvement
Content
validity
The degree to which the content of an HR-PRO instrument is
an adequate reflection of the construct to be measured
+ A clear description is provided of the measurement aim,
target population, the concepts that are measured, and the
item selection and target population were involved in item
selection
+/− A clear description of these aspects is lacking, or only
target population involved, or doubtful design or method
- No target population involvement
Construct
validity
The degree to which the scores of an HR-PRO instrument are consistent
with hypotheses (for instance with regard to internal relationships,
relationships to scores of other instruments, or differences between
relevant groups) based on the assumption that the HR-PRO
instrument validly measures the construct to be measured
+ Specific hypotheses were formulated and at least 75 %
of the results are in accordance with these hypotheses
+/− Doubtful design or method (e.g. no hypotheses)
- Less than 75 % of hypotheses were confirmed
Responsiveness The ability of an HR-PRO instrument to detect change over time in
the construct to be measured
+ SDCb or SDC ˂ MICc or MIC outside the LoAd or RRe ˃
1.96 OR AUCf ≥0.70
+/− Doubtful design or method
- Negative SDC or SDC≥MIC or MIC equals or inside LOA
or RR ≤1.96 OR AUC ˂0.70, despite adequate design and
methods
aICC Intraclass Correlation Coefficient
bSDC Smallest Detectable Change
cMIC Minimal Important Change
dLoA Limits of Agreement
eRR Responsiveness Ratio
fAUC Area Under the receiver operating characteristics Curve
Fig. 1 The number of articles in- and excluded in the SR
Fig. 2 Venn-diagram depicting the number of studies in the categories
drug-studies and methodology studies, and the number of studies in
both categories
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Table 2 Reported Patients, Interventions, Comparisons and Outcomes in the included studies





Cusick [29] 2006 Children with spastic hemiplegic
cerebral palsy









De Beurs [20] 1993 Patients meeting the DSM-III-R
criteria for panic disorder with
moderate or severe agoraphobia
Fluvoxamine & exposure in vivo,
panic management & exposure in
vivo, exposure in vivo only









Rockwood [27] 1996 Patients with Alzheimer’s
Disease of mild to moderate
severity






Rockwood [50] 2002 Patients with mild to moderate
Alzheimer’s Disease
Donepezil hydrochloride 5 mg 1
daily
None GAS, Cognition (MMSE, ADAS-cog),
physical function (PSMS, IADL, FAQg),





Steenbeek [38] 2005 Children with cerebral palsy BTX-A treatment of the lower
extremity






Ashford [51] 2009 Proximal upper limb spasticity
patients
BoNT-A as part of a shoulder and
upper limb management and
rehabilitation program which was
individually tailored to the patient
None GAS, MAS (composite spasticity






Barden [52] 2014-a Participants with spasticity
following acquired brain injury
Botulinum toxin A injections None Dynamic Computerized
Dynamometry, MAS, Tardieu Scale,
Action Research Arm Test, GAS,






Barden [53] 2014-b Convenience sample of adults with
upper limb spasticity after acquired
brain injury with a mean age of 51






Bonouvrié [54] 2013 Dystonic cerebral palsy patients aged
4–25 years
Continuous intrathecal baclofen for
3 months
Placebo GAS, measurements of body







Borg [55] 2011 Adults with a stroke that occurred
>3 months before the study
Botulinum toxin A + standard care Placebo + standard care GAS, changes from baseline in level
of goal achievement, health related





Demetrios [56] 2014 Adults with post-stroke spasticity High intensity ambulatory
rehabilitation and Botox






















Ferrari [57] 2014 Children with hemiplegic cerebral
palsy
BoNT-A injections Placebo-injections Body functions and structure, activity














Saline (placebo) Carer burden scale, GAS, Ashworth
scale, passive range of movement for
shoulder abduction, elbow and






Lam [60] 2015 Long-term care patients with bilateral
severe chronic hip adductor spasticity
Ultrasound and electrical
stimulation guided obturator





MAS, GAS, hygiene score, distances
between the knees, passive range of
motion, pain (Pain Assessment in
Advanced Dementia Scale),






Leroi [61] 2014 Patients with dementia in Parkinson’s
disease







Löwe [62] 2006 Children with hemiplegic cerebral
palsy, aged 2–8
Occupational therapy & BTX-A
injections
Occupational therapy QUESTr, average treatment effect,





Löwe [63] 2007 Children with hemiplegic cerebral
palsy
3 BTX-A injections
(0, 6 and 18 months)
2 BTX-A injections (6 and
18 months)
QUEST, GAS-parents, GAS-therapist,
COPM, Pediatric Evaluation of






Mall [64] 2006 Children with CP and adductor
spasticity
BTX-A injections Placebo Knee-knee distance, hip adduction,
modified Ashworth scale, GMFMu,






McCrory [65] 2009 Adults with hemiplegic stroke, severe/
moderately severe spasticity
Botulinum toxin for upper
limbs
Placebo QoLv, GAS, pain, mood, global






Molenaers [66] 2013 CP patients with lower limb BTX-A
treatment, younger than 24 years of
age




















Nott [67] 2014 Community dwelling adults with
acquired brain injury















Rice [69] 2009 Children with predominantly dystonic
CP

















Rockwood [72] 2007-b Patients diagnosed with mild to
moderate AD
5 mg of donepezil for 3
months, thereafter flexibly
dosed (5 or 10 mg)





Rockwood [73] 2010 Mild to moderate Alzheimer’s Disease
patients
Flexibly dosed galantamine for
16 weeks, followed by 16 week
open-label phase






Russo [74] 2007 Children (3–16 years) with hemiplegic
cerebral palsy
Localized injection of BTX-A and
4 weeks of occupational therapy
4 weeks of occupational
therapy
Body structure (Tardieu scale,






Scheinberg [75] 2006 Children aged between 1 and
15 years with CP and clinically
significant spasticity
Oral baclofen Placebo GAS, MTSal, PEDI, parental satisfaction





Schramm [76] 2014 Patients aged 18 years or older with
focal or segmental spasticity showing
indication for treatment
Onabotulinum toxin A None MASam, spasticity pattern, pain, active
hand function, FACan, gait, timed up







Turner- Stokes [77] 2007 Patients with regional spasticity
following acute stroke or brain injury
intervention
Serial injections of botulinum
toxin
None MAS, Associated Reaction rating






















Wallen [78] 2004 Children with spastic cerebral palsy
between the age of 1 and 14 years
Botulinum toxin type A injections None COPMap, GAS, Melbourne
assessment, CHQaq, parent






Wallen [79] 2007 Children with CP affecting 1 or both
upper limbs, aged 2–14
Single set of BTX-A injections and
12 weeks of occupational therapy
Only occupational
therapy or no treatment





Ward [80] 2009 Children with spasticity and/or
dystonia, as classified by a
rehabilitation consultant





Ward [81] 2014 Adults with focal post-stroke spasticity Onabotulinumtoxin-A + standard of
care
Placebo + standard of
care
Number of patients achieving their
principal active functional goal, or






Bovend’Eert [37] 2011 Hospital patients with neurological
disorders participating in a RCT
A motor imagery program
integrated into physiotherapy and






Brown [32] 1998 Nonambulatory patients who had
limited adaptive behavior












None GAS, timed tests of physical mobility










None Effect size and relative efficiency of
the Barthel Index, hierarchical
assessment of balance and mobility,
global deterioration scale, axis 8
(behavior) of the brief cognitive






Hartman [39] 1997 Residents of a SCU for persons with
dementia
None None GAS, COPMay, Cognitive Competency







Khan [40] 2008 Persons with MS admitted for
comprehensive rehabilitation program





















Palisano [21] 1993 Infants (4–24 months) with motor
delays
2-h intervention session by an
interdisciplinary team
None GAS, Peabody Developmental Gross
Motor Scale, behavioral objective,





Rockwood [31] 1993 Geriatric patients admitted to geriatric
inpatient wards
None None GAS, Barthel Index, Functional
Independence Measure, Physical Self-
Maintenance Scale, Katz Activities of






Rockwood [33] 1997 Patients undergoing cognitive
rehabilitation
None None GAS, Rappaport Disability Rating
Scale, Kohlman Evaluation of Daily
Living Skills, Milwaukee Evaluation of
Daily Living, Kleinbell elimination
scale and mobility scale, Instrumental
Activities of Daily Living Scale, Spitzer





Rockwood [41] 2003 Frail elderly Specialized geriatric intervention usual care GAS, Barthel Index, Physical Self-
maintenance scale, instrumental
activities daily living, modified Spitzer










Ruble [36] 2013-a Autism patients Web based and face-to-face
coaching sessions
Placebo Goal attainment (PET-GASba), process






Ruble [34] 2013-b Autism patients Face-to-face, Compass intervention/





PET-GAS, language ability, autism





















Stolee [26] 1999 Geriatric patients Care as usual None GAS, self-rated health, global clinical
assessment, Barthel Index, OARS




















Stolee [22] 2012 Patients admitted to a geriatric day
hospital





Turner-Stokes [42] 2009 Consecutive patients admitted for
rehabilitation following acquired brain
injury (any cause) over 3 years
Neuro rehabilitation intervention None GAS, Functional Assessment Measure





Turner-Stokes [43] 2010 Upper-limb spasticity patients (after
stroke)
Intramuscular botulinum toxin-A Placebo GAS, MASbg, Global Benefit, HADSbh,








2013 Adults with post-stroke upper limb
spasticity treated with one cycle of
BoNT-A
Botulinum toxin A None GAS, spasticity, standardized





Woodward [28] 1978 Families with a child between 6 and
16 years of age who was referred for
academic or behavioral problems at
school





Yip [23] 1998 Patients admitted to the Geriatric
Assessment and Rehabilitation Unit
Rehabilitation interventions None GAS (a modified version that uses a
standardized menu of goals and
attainment levels)
aCOPM Canadian Occupational Performance Measure
bMMSE Mini-Mental State Examination
cADAS-cog Alzheimer’s Disease Assessment Scale - cognitive subscale
dPSMS Physical Self-Maintenance Scale
eIADL Instrumental Activities of Daily Living
fCGI Clinical Global Impression
gFAQ Functional Activities Questionnaire
fCDS Cardiac Depression Scale
iCES-D Center for Epidemiological Studies Depression Scale
jCIBIC-plus Clinician’s Interview-Based Impression of Change-Plus
kMAS Modified Ashworth Scale
lDCD Pinch Dynamic Computerized Dynamometry
mARAT Action Research Arm Test
nMHOQ Michigan Hand Outcomes Questionnaire
oMAS Modified Ashworth Scale
pAHA Assisting Hand Assessment
qPEDI Pediatric Evaluation of Disability Inventory
rQUEST Quality of Upper Extremity Skills Test
sCOPM Canadian Occupational Performance Measure
tPEDI Pediatric Evaluation of Disability Inventory
uGMFM Gross Motor Function Measure
vQoL Quality of Life
wMAS Modified Ashworth Scale
xTSA Tardieu Spasticity Angle
yARAT Action Research Arm Test















aaQUEST Quality of Upper Extremity Skills Test
abPDMS-FM Peabody Developmental Motor Scale – Fine Motor
acMTS Modified Tardieu Scale
adBAD-scale Barry-Albright Dystonia scale
aeADAS-cog Alzheimer’s Disease Assessment Scale - cognitive subscale
afCIBIC-plus Clinician’s Interview-Based Impression of Change-Plus
agDAD Disability Assessment for Dementia
ahCBS Caregiving Burden Scale
aiAMPS Assessment of Motor and Process Skills
ajPEDI Pediatric Evaluation of Disability Inventory
akQoL Quality of Life
alMTS Modified Tardieu Scale
amMAS Modified Ashworth Scale
anFAC Functional Ambulation Category
aoLASIS Leeds Adult Spasticity Impact Scale
apCOPM Canadian Occupational Performance Measure
aqCHQ Child Health Questionnaire
arMAUULF Melbourne Assessment of Unilateral Upper Limb Function
asCOMP Canadian Occupational Performance Measure
atMPQ McGill Pain Questionnaire
auNRS Pain Intensity Numerical Rating Scale
avODQ Oswestry low back pain Disability Questionnaire
awGHQ General Health Questionnaire
axPAIRS Pain and Impairment Relationship Scale
ayCOPM Canadian Occupational Performance Measure
azFIM Functional Independence Measure
baPET-GAS Psychometrically Equivalence Tested Goal Attainment Scaling
bbPEDI Pediatric Evaluation of Disability Inventory
bcGMFM Gross Motor Function Measure
bdOARS IADL Older Americans Resource Scale for Instrumental Activities of Daily Living
beMMSE Mini-Mental State Examination
bfNHP Nottingham Health Profile
bgMAS Modified Ashworth Scale
bhHADS Hospital Anxiety and Depression Scale















the use of Fluvoxamine in patients who met the criteria
for panic disorder with moderate to severe agoraphobia.
GAS was used as a primary outcome measure. Both
therapists and independent raters who assessed the level
of goal attainment after the intervention, were asked to
rate the relevance of the chosen goals on a scale of 1 to
5 (with one meaning irrelevant and five meaning very
relevant). Therapists only rated the GAS score of pa-
tients not treated by themselves. The mean score of the
therapists was 4.68 (SD = .51), and the mean score of the
independent raters was 4.66 (SD = .52). The researchers
concluded that these numbers show that ‘the goal areas
were suitably chosen’. The target population of GAS (the
patients) were not involved in this evaluation, which is
one of the requirements of the quality criteria that we
use. However, it is inherent in the measurement instru-
ment that the patient is involved in the choice of the
items. Therefore, we score the quality of the face validity
evaluation as ‘good quality’.
Content validity
Content validity was reported in five studies, of which
one was a drug study. Content validity was measured in
several ways, as shown in Table 5; by rating the useful-
ness or importance of the goals [21, 22], by comparing
the goal areas with essential components as recom-
mended by position papers in the specific field [23] and
by checking whether the goals were formulated accord-
ing to the criteria ‘Specific, Measurable, Assignable,
Realistic, and Time-related’(SMART) [24, 25]. In one
Table 4 Reported measurement properties of GAS in included validity studies
Author Year Face validity Content validity Construct validity Intra-rater reliability Inter-rater reliability Responsiveness
Bovend’Eert 2011 - - - - + -
Brown 1998 - - - - + -
Fisher 2002 - - + - - -
Gordon 1999 - - + - - +
Hartman 1997 - - - - - +
Khan 2008 - - + - - +
Palisano 1993 - + + - + +
Rockwood 1993 - - + - + +
Rockwood 1997 - - + - + +
Rockwood 2003 - - - - - +
Ruble 2012 - - - - + -
Ruble 2013-a - - - - + -
Ruble 2013-b - - - - + -
Sheldon 1998 - - + - - -
Steenbeek 2011 - - + - - +
Stolee 1999 - + + - + +
Stolee 2012 - + - - - +
Turner-Stokes 2009 - - + - - +
Woodward 1978 - - + - + -
Yip 1998 - + + - - +
Table 3 Reported measurement properties of GAS in included drug studies
Author Year Face validity Content validity Construct validity Intra-rater reliability Inter-rater reliability Responsiveness
Cusick 2006 - - + - - +
De Beurs 1993 + - + - + -
Rockwood 1996 - - + - - -
Rockwood 2002 - - + - - -
Steenbeek 2005 - - - - + -
Turner-Stokes 2010 - - + - - +
Turner-Stokes 2013 - + + - - -
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study, the content validity was reportedly tested by
grouping the goals into major categories, and analyzing
the content of these categories [26]. However, the study
did not report the results of the categorization of the
goals [26]. The quality of the content validity varied
from ‘good quality’ in two studies, ‘intermediate quality’
in two studies and ‘poor quality’ in one study. Authors
reported a ‘good overall usefulness’ of the goals [22],
stated that all recommended areas were represented in
the goals [23], whether goals were set according to the
SMART principle (in this particular study, it was con-
cluded that there was, even after a refinement process of
the goal statements, still a difference in the quality of
the goal statements between the different sites) [24, 25]
or that more than 70 % of the responders rated GAS as
a 4 or 5 on a 5-point scale as clinically relevant and
important [21].
Construct validity
Construct validity was reported in 18 studies, of which
six were drug studies (Table 6). In all 18 studies con-
struct validity was assessed by correlations with other in-
struments measuring a construct similar to the goals
that were expected to be set by the patients in each spe-
cific research area. Also, T-tests between the placebo
and intervention condition [27], or T-tests between the
lowest and highest T-score differences [28], were used to
verify construct validity. In none of the studies, a hy-
pothesis was formulated on the expected construct val-
idity outcomes. Therefore, the quality of the construct
validity is difficult to evaluate. Of the 18 studies, 14 re-
ported significant correlations with other measurement
instruments that were relevant for the research area.
The measurement instruments used to establish the
construct validity varied considerably, since GAS is used
Table 5 Reported content validity of GAS in included studies
First author Year Drug study N Methods and results Quality
Palisano 1993 No 21 10 physical therapists rated 10 randomly selected GAS-goals
on a five-point scale on importance (88 % rated a 4 or 5),
the expected level of goal attainment (77 % rated 4 or 5)
and clinical relevance (79 % rated a 4 or 5). Between 77
and 88 % of the ratings met the criterion.
+
A clear description is provided of the
measurement aim, and target population
is inherently involved in item selection
Stolee 1999 No 173 Goals were grouped in major categories, of which the most
common were mobility, future care, personal care and bowel
and bladder problems. The categorization was reviewed by
clinicians of the geriatric rehabilitation unit. The results of this
review were not mentioned in the article.
-
No results mentioned
Stolee 2012 No 90 Clinicians rated the use of GAS with a mean of 3 (SD 0.9) on
a 5-point scale, indicating a “good overall usefulness” of GAS.
+
A clear description is provided of the
measurement aim, and target population
is inherently involved in item selection
Turner-
Stokes
2013 Yes 456 Goal statements for the primary goal in each patient were
independently evaluated by three lead clinical investigators,
in two rounds. The purpose was to check that clinicians were
setting SMART function-related goals in accordance with the
training. Goal statements were rated an A, B or C, where an
A-rating means ‘Some goal statements contain reference to
functional activities at the level of disability or participation—
may be ‘active’ or ‘passive’ function’, a B-rating means that ‘Goal
statements contain reference to impairment only’, and a
C-rating means ‘Goal statements contain reference to anatomical
structures only’. Also, a ++, + or – was added, where ++ means
‘There is a SMART goal description, sufficiently detailed and
specific to make accurate GAS rating’, + means ‘There is some
clear goal description sufficient to support GAS rating, but still
reliant on subjective interpretation’ and – means ‘No clear goal
\description’. The rating was done in two rounds: after the first
round, 62.7 % recorded function-related statements rated A or AB,
and 40.3 % of the goal statements received a SMART quality
rating of A+/A++. In round two these figures rose to 70.9 and
46.8 % respectively. The authors conclude that even after this
goal refinement process, there is residual heterogeneity between
the quality of the goals in the different sites that were included
in the study.
+
A clear description is provided of the
measurement aim, and target population
is inherently involved in item selection
Yip 1998 No 143 Content validity was evaluated by comparison of identified goal
areas with the essential components of geriatric assessment
recommended by several position papers. All the
recommended domains were assessed.
+/−
Unclear how and by whom the
evaluation was scored
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N Methods and results Quality
Cusick 2006 Yes 41 Correlations with COMP and GAS Likert scale were measured; no correlation
higher than −0.25 or with a p-value lower than 0.05.
+/−
No hypotheses
De Beurs 1993 Yes 40 Correlations with agoraphobia, rating of treatment outcome by therapist,
M-BAT, depression and somatic anxiety were measured; GAS has a high
correlation with gain scores on agoraphobia (0.63), rating of treatment
outcome by therapist (0.43), and M-BAT (0.57). GAS is moderately correlated
with depression (0.32), and not significantly correlated with somatic anxiety.
+/−
No hypotheses
Fisher 2002 No 149 Correlations with improvements in walking, general health questionnaire,
Oswesty Low Back Pain Disability Questionnaire, NRS and change stand-sit
and change PAIRS were measured. There was a significant correlation
between GAS and improvements for walking (0.47), between GAS and the
general health questionnaire (0.25) and between GAS and the OLBPDQ
(−0.31), with p <0.01 for all three. No significant correlations were found
between GAS and the NRS and change stand-sit and change PAIRS.
+/−
No hypotheses
Gordon 1999 No 53 Correlations with standard scales of cognition (MMSE and Global Deterioration
Scale), behavior (axis 8 of the brief cognitive rating scale), co-morbidity
(cumulative illness rating scale), mobility and balance (hierarchical assessment
of balance and mobility, HABAM), and functional capacity (Barthel Index); GAS




Khan 2008 No 24 Correlation with Barthel Index, Functional Independent Measure and Clinical
Global Impression was measured; only the correlation with CGI was significant
(−0.77). Also, the difference between responders and non-responders was
measured, and a significant difference was found (Z = −3.78, p <0.001).
+/−
No hypotheses
Palisano 1993 No 21 Correlations between GAS T-scores and Peabody Gross Motor Age equivalent
change scores were measured; none of these correlations were significant.
+/−
No hypotheses
Rockwood 1993 No 45 Correlations with change scores of Barthel Index, Functional Independent
Measure, Mini-Mental State Examination, Katz ADL Index, Physical
Self-Maintenance Scale, and Spitzer Quality of Life Index were measured.





Rockwood 1996 Yes 15 A correlation with change scores is measured between GAS and Alzheimer’s
Disease Assessment Scale-cognitive, Global Deterioration Scale, Clinical Global
Impression, Mini-Mental State Examination, Physical Self Maintenance Scale,
and the Instrumental Activities of Daily Living. Correlations varied from −0.85
to 0.74, but it is unclear if these correlations are significant. A T-test between
the placebo and the intervention condition was also performed. The T-test




Rockwood 1997 No 44 Correlations with two measurement instruments were measured: Clinical
Global Impression (r = 0.73) for change score and (r = 0.63) at discharge.
+/−
No hypotheses
Rockwood 2002 Yes 108 Correlations were measured between several goals within GAS and other
measurement instruments. Mini-Mental State Examination and GAS cognition
goals: r = 0.51. Alzheimer’s Disease Assessment Scale-cognitive and GAS
cognition goals: r = −0.43. Physical Self Maintenance Scale and clinical function
goals: r = −0.53. Patient-carer function goals and Physical Self Maintenance
Scale: r = −0.47. Patient-carer function goals and Instrumental Activities of
Daily Living: r = −0.44.
+/−
No hypotheses
Sheldon 1998 No 82 GAS was correlated with the ‘rated attainment’ scale: r = 0.71 (p <0.001). There
was a correlation with autonomy (r = 0.21, p <0.01), later effort (r = 0.42, p <0.01)
and autonomous reasons (r = 0.09, p <0.05).
+/−
No hypotheses
Steenbeek 2011 No 23 Correlation with Pediatric Evaluation of Disability Inventory Functional Status
Score Mobility: r = 0.64 (p <0.01), correlation with PEDI Selfcare and social
function was not significant.
+/−
No hypotheses
Stolee 1999 No 173 Change and follow-up scores of GAS were correlated with Barthel Index, Older
Americans Resource Scale Instrumental Activities of Daily Living, Mini-Mental
State Examination, Global Rating, Nottingham Health Profile. The correlations





2009 No 164 Correlations were measured between GAS and Functional Independent Measure
and Functional Assessment Measure. Correlations with FIM + FAM scores were
moderate: 0.36–0.43 for raw scores, 0.41–0.49 for GAS transformed FIM + FAM scores.
+/−
No hypotheses
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for different research areas. Three studies reported that
no significant correlations with other measurement in-
struments were found [21, 29, 30]. In one study correla-
tions between change scores were measured. The results
were not clearly reported [31].
Intra- and inter-rater reliability
As can be seen in Tables 3 and 4, intra-rater reliability
was not assessed in any of the included studies. Inter-
rater reliability was reported in 12 studies, of which two
were drug studies. Different methods were used to
measure the inter-rater reliability (Table 7). In four stud-
ies we rated the quality of the inter-rater reliability as
poor, whereas eight studies were rated with ‘good qual-
ity’. Eight out of the 12 studies reported an ICC score.
Five of those studies reported that the ICC values were
all 0.9 and higher [31–35]. Two studies reported ICC
values between 0.8 and 0.95 [26, 36]. In one study, the
reported ICC was lower than 0.5 [37]. The specific cal-
culation for the ICC was reported in one study [37].
Confidence intervals for the ICC values were also re-
ported in one study [35]. Inter-rater reliability was also
reported with kappa-values [21, 38], where the values
ranged from substantial to almost perfect agreement.
Another method that was used was calculating a correl-
ation, which had a value of 0.84 [28]. One study reported
‘agreement’ between objective goal setters and the
therapists who performed the interventions, and ‘agree-
ment’ between objective goal setters and people who did
the intake of the patients before the patients were ran-
domized. The results were an agreement of 43 and 57 %
respectively. However, in the article the method used to
calculate this agreement were not reported [20].
Responsiveness
Responsiveness was reported in 14 studies, of which two
were drug studies (Table 8). None of the studies used
measurement properties as advised by Terwee et al. [19].
Therefore, it is difficult to evaluate the quality of the re-
sponsiveness. In nine of those 14 studies, an effect size
of the measured differences was reported [26, 29–31, 33,
39–42]. Of those nine studies, the reported effect size
was below 1 in only one study [29]. In five studies, a
Relative Efficiency was reported [26, 30, 31, 33, 41]. The
relative efficiency of two procedures or measurement in-
struments is the ratio of their efficiencies. For instance, a
comparison can be made between GAS and a regularly
used measurement instrument. The Relative Efficiency
varied between 3 and 57, but was substantial in most stud-
ies, meaning that GAS is more efficient, or needs less
observations, than other measurement instruments. A
Standardized Response Mean was reported in six studies
[22, 23, 26, 40–42]. A standardized response mean (SRM)
is an effect size index used to measure the responsiveness
of scales to clinical change. The SRM is computed by
Table 6 Reported construct validity of GAS in included studies (Continued)
Turner-
Stokes
2010 Yes 90 Correlations were measured between GAS and a composite spasticity score
(MAS), Global Benefit patient report, Global Benefit investigator report, Hospital
Anxiety and Depression Scale anxiety and Hospital Anxiety and Depression
Scale depression, Pain at rest, Pain on movement, Assessment of Quality of
Life, Patient Disability Score, and Carer burden score. Significant correlations
between GAS and MAS (0.35), Global benefit patient report (0.46) and Global






2013 Yes 456 Correlations between GAS and ‘other measures of outcome, e.g. measures of
spasticity, global benefit and other standardized measures’ were calculated.
GAS correlated weakly with a reduction in total Modified Ashworth Scale at
follow-up (Sp r = 0.28, p <0.0001) and with global assessment of benefit




Woodward 1978 No 279 GAS scores correlate significantly with other outcome measures: r = 0.12 - 0.39;
p <0.05 (in the paper, it is not clear what these other outcome measures are).
There was also a difference between the highest and lowest T-score differences:
the highest scorers had a mean pre-post score difference of 42.70 (SD = 6.87),
the lowest scorers had a mean pre-post difference of 4.05 (SD = 5.78).
+/−
No hypotheses
Yip 1998 No 143 Correlations with the Standardized Mini-Mental State Examination, the modified
Barthel Index, the Katz Index of ADL and the IADL subscale of the Older Americans
Resources and Services Questionnaire were used to demonstrate the convergent
construct validity of the standardized menu of GAS. Spearman correlations were
calculated between GAS summary scores at discharge and change scores on
the Barthel, Katz, OARS-IADL, and SMMSE. The correlations of the total GAS score
with changes on the three measures of function were statistically significant but
modest (r = 0.41 to 0.45); the correlation of GAS with the SMMSE change score
was not significant (r = 0.11).
+/−
Modest correlations
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dividing the mean change score by the standard deviation
of the change. The SRM’s that were reported varied be-
tween 1.2 and 3.54. Two studies measured responsiveness
with a paired t-test comparing response before and after
the intervention, with a significant difference in GAS T-
scores in both studies [22, 39]. In one study, the sensitiv-
ity, specificity and positive and negative predictive value
were calculated based on a group of responders and non-
responders [43]. The results were 52, 85, 81 and 60 %, re-
spectively. In another study, responsiveness was reported
as the number of patients who showed a change in T-
scores of different goal areas [44]. The proportion of pa-
tients showing changes on GAS was larger than on other
measurement instruments. The number of patients show-
ing change were nine out of 23 patients on the physical
goals, 18 out of 23 patients on occupational goals and 12
Table 7 Reported inter-rater reliability of GAS in included studies
First author Year Drug study N Methods and results Quality
Bovend’Eert 2011 No 29 Mixed model ICC(a, k) between therapist and masked assessor
scoring procedures is 0.478 (low); LoA −1.52 +/− 24.54.
-
ICC ≤0.7
Brown 1998 No 24 The Pearson’s r correlations and inter-rater ICCs (2,1) between the
scores of the treating therapist and the independent raters were
r = 0.84 (p <0.0001, n = 360, r2 = 70.90/0) and ICC = 1.00 (between
raters: (IF = 1, SS = 0.01; within raters: df = 695, SS = 1, 172.65),
respectively. The coefficients between scores of the 2 independent
raters were r = 0.81 (p <0.0001, n = 135, rZ = 66.2 %) and ICC = 0.997
(between raters: dl = 1, SS = 1.48; within raters: f = 245, SS = 433,39).
The results support acceptable inter-rater reliability of the scores for
the goals in this study.
+
ICC ≥0.7
De Beurs 1993 Yes 40 Agreement on the content of the chosen goals was measured between
the intakers, in other words the people who performed the first session
before the patients were randomized, and therapists was measured.
Also, the agreement between the therapists and the people who
objectively set the goals, or the goal setters, was measured. Agreement
between goal setters and therapists and between goal setters and
intakers was 43 and 57 % respectively. The calculations used to establish





Palisano 1993 No 21 Before data collection, an inter rater reliability was measured between
the author and an examiner (Kappa = 0.89, agreement 90 %). During
the study 16 goals were simultaneously scored. The agreement was
88 % (Kappa = 0.75).
+
ICC ≥0.7
Rockwood 1993 No 45 A primary nurse and a multidisciplinary team scored GAS, ICC = 0.91. +
ICC ≥0.7
Rockwood 1997 No 44 ICC = 0.95 for admission scoring, ICC = 0.95 for discharge scoring,
ICC = 0.93 for change score.
+
ICC ≥0.7
Ruble 2012 No 35 + 44 (reference
to previous study)
Two raters independently coded 20 % of the GAS forms for the
three features of agreement in sample 1 and 2. ICC for average
agreement in sample 1 on measurability (0.96, 95 % CI [.87, .99]),
difficulty (0.59, 95 % CI [−.18, .81]) and equidistance (0.96, 95 % CI
[.74, .99); ICC for average agreement in sample 2 on measurability
(1.0), difficulty (0.96, 95 % CI [.83, .99]) and equidistance





Ruble 2013-a No 49 Two coders independently coded 39 % of the goals, ICC for social




Ruble 2013-b No Not stated
(reference to
previous study)
Excellent inter-rater reliability was achieved for both study 1
(ICC = 0.99) and study 2 (ICC = 0.90).
+
ICC ≥0.7
Steenbeek 2005 Yes 11 A video scoring and scoring by a physiotherapist were compared,
gaining a Kappa of 0.63. 5 out of 33 of the goal scores differed
significantly (tested with a Wilcoxon signed rank test).
-
k ≤0.7
Stolee 1999 No 173 ICC (N = 61) = 0.93 of GAS follow-up score. ICC (N = 61) = 0.89 of the
separate goals, when checked whether the goals have been attained.
+
ICC ≥0.7
Woodward 1978 No 279 Correlation of two goal attainment scores: 0.84. 33 % scored identical,
78 % within one level, 95 % within two levels. GAS scores did not
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out of 18 patients on speech goals, whereas there was only
one patient that showed change on the Gross Motor
Function Measure (GMFM-66).
Discussion
In this systematic review, we have found 58 articles, of
which 38 drug studies, where GAS was used as an
outcome measure. Therefore, we may conclude that
GAS has indeed been used in drug studies. Most drug
studies that report any information on the validity of
GAS, used Botulinum Toxin as an intervention for spas-
ticity, usually in combination with physical or occupa-
tional therapy. The generalizability of the results of these
validation studies is limited. The validity, responsiveness
Table 8 Reported responsiveness of GAS in included studies
First author Year Drug study N Methods and results Quality
Cusick 2006 Yes 41 Ability to detect change overtime, and ability to detect difference in change between
groups was measured with regression coefficients and effect sizes. Effect size for the




Gordon 1999 No 53 GAS was the most responsive measure, with the highest effect size (1.29) and the




Hartman 1997 No 10 Effect size statistic of 2.34; paired t-test before-after of 2.9 (df = 9, p = 0.017). +/−
Doubtful design
or method
Khan 2008 No 24 Effect size 9.0, t = 10.0, Standardized response mean = 2.4 +/−
Doubtful design
or method
Palisano 1993 No 21 Of the 84 goals that were formulated for the study, similar information was obtained
with the behavioral objective and GAS formats for 33 (39 %) of the goals, and change
that could not be measured with the behavioral objective format was measured with
the GAS format for 51 (61 %) of the goals. Of the 17 behavioral objectives that were
not achieved, the corresponding GAS score documented progress toward the expected
outcome (score of - 1) for 2 (12 %) of the goals. Of the 67 behavioral objectives that
were achieved, the corresponding GAS score documented progress that exceeded
he criteria for achievement of the behavioral objective (score of +1 or +2) for 49




Rockwood 1993 No 45 RE = 4.5; ES = 5.0 +/−
Doubtful design
or method
Rockwood 1997 No 44 Relative efficiency: 7.8; Effect size: 5.11 +/−
Doubtful design
or method
Rockwood 2003 No 265 GAS was more responsive than other measures for functional improvement in the elderly;




Steenbeek 2011 No 23 Individual change score was found in 9/23 (physical), 18/23 (occupational) and 12/18




Stolee 1999 No 173 GAS ES = 3.52; Standardized response mean = 1.73; Relative efficiency = 3.14 +/−
Doubtful design
or method
Stolee 2012 No 90 All three measures of responsiveness indicated that GAS was able to detect meaningful





Turner-Stokes 2009 No 164 SRM: non-weighed GAS = 2.23, weighed GAS = 2.29. Effect sizes: non-weighed GAS = 3.16,




Turner-Stokes 2010 Yes 90 The group was divided in responders and non-responders, based on the basis of their
mean global benefit at the end of the study; across the whole sample, a change in GAS
score from baseline of 6 predicted a positive response, with 52 % sensitivity, 85 %




Yip 1998 No 143 Standardized Response Mean was calculated for each instrument, by dividing the mean
difference between post-treatment and pre-treatment status by the standard deviation
of the mean change score. The SRM was 1.56 for GAS, compared with 0.89, 0.82, 0.72
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and reliability of GAS in drug studies have scarcely been
studied. In only seven of the 38 drug studies that we
found, some validation has been performed. The
methods used to validate the measurements instruments
often differ from the methods as proposed by COSMIN.
The quality of the methods to assess measurement prop-
erties varies, and results are often difficult to interpret.
We found 20 articles concerning non-drug studies
reporting on the validity, responsiveness and inter-rater
reliability of GAS. However, also in studies in which
GAS was used to evaluate a non-drug intervention, the
quality of the validity reports leaves much room for
improvement.
In most articles, either drug or non-drug studies, no
definition was given of the measurement properties that
were assessed, the formulae used for calculation of pa-
rameters were not presented, and in some papers the re-
sults of the validity check were not reported [26, 31].
Also, none of the included articles describe hypotheses
to test construct validity, which makes evaluating the re-
ported results virtually impossible. Therefore, we con-
clude that the validity and reliability of GAS have not
been researched extensively, neither in studies where a
drug intervention was evaluated, nor in other studies.
Of all clinimetric characteristics that were investigated,
the responsiveness of GAS was investigated most thor-
oughly. The responsiveness was consistently reported to
be very good compared to other measurement instru-
ments, such as the Gross Motor Function Measure
(GMFM-66) in the evaluation of children with cerebral
palsy, or the Standardized Mini Mental State Examin-
ation (SMMSE) for geriatric assessment. However, none
of the studies evaluated the responsiveness according to
the guidelines as proposed by Terwee et al. [19]. There-
fore, it is difficult to be conclusive on the responsiveness
of GAS, although the reported results suggest we may
tentatively be optimistic.
The search of this systematic review was very sensitive,
to make sure that no studies on GAS were missed. How-
ever, our definition of GAS is rather specific, which ex-
cludes studies with an approach that is similar, but not
exactly the same. Also, we may have missed studies that
did not use similar terminology, but did use an approach
similar to GAS.
Our findings are consistent with previous systematic re-
views on the measurement properties of GAS. For instance,
Steenbeek et al. [10] concluded that, in the setting of
pediatric rehabilitation, GAS is a very responsive method
for treatment evaluation and individual goal setting, but
sufficient knowledge is lacking about its reliability and val-
idity, particularly. Also, in the field of psychogeriatrics, GAS
may be considered useful from a theoretical point of view.
Geriatric patients are heterogeneous, and GAS may be a
useful tool to evaluate geriatric interventions. However, the
measurement properties of GAS in geriatrics show mixed
results. The evidence is not yet strong enough to state that
GAS is an applicable outcome measure in this particular
field [14]. In a systematic review on the feasibility of meas-
urement instruments related to goal setting, GAS is consid-
ered a helpful tool for setting goals, although it is time-
consuming and may be difficult for patients with cognitive
impairments. However, the patient-centered nature of GAS
makes it easier to focus on meaningful patient-directed
treatment goals. Also, according to the results the scaling of
GAS makes it possible to detect very small progress that
may be of great significance to the patient, underlining its
potential in responsiveness [45].
A problem in the evaluation of the validity of GAS
may be that GAS does not measure one clear construct,
since the content of the goals generally differs from pa-
tient to patient. One of the possibilities to overcome this
inherent problem may be to make an item bank of pos-
sible goals that patients would be able to choose from,
to make sure that the methodological properties of the
goals are known [46]. However, this would be practically
very difficult to achieve, since we suspect that for many
orphan diseases the patient numbers are smaller, and
goals could be more diverse than those of non-orphan
disease patients. Another way of approaching the con-
struct validity is to see GAS as a measurement instru-
ment that measures the construct of the attainment of
goals. Then, the construct validity could be evaluated by
comparing GAS with another measurement instrument
that evaluates the attainment of goals, such as the
COPM. To our knowledge, this approach has not been
considered so far.
The importance and difficulty of goals are often taken
into account by assigning weights to the goals (more im-
portant goals are assigned a larger weight then less im-
portant goals). However, terms such as importance and
difficulty are by nature subjective. What is important for
one patient, may be less important for another. For ex-
ample, a Duchenne patient may perceive being able to
brush his teeth as very important, where someone else
may conceive it as trivial. Can this difference in import-
ance objectively be measured? In a study on the reliabil-
ity of GAS weights, Marson, Wei and Wasserman [47]
conclude that assigning weights to the goals of GAS ac-
cording to the severity of the problem has an acceptable
inter-rater reliability when scored by different objective
students trained in the use of GAS. This indicates that
although importance and difficulty are difficult to object-
ively measure, objective raters may still score goals simi-
larly. However, more research should be carried out on
this topic to answer the question more definitively.
GAS is a measurement instrument with a high potential,
especially in rare diseases, but in order to use it in drug
studies, more research on its validity is essential. One way
Gaasterland et al. BMC Medical Research Methodology  (2016) 16:99 Page 18 of 22
of achieving this would be to use GAS as an additional
measurement instrument in an ongoing drug trial, to fur-
ther explore its validity. For GAS to be possibly useful, the
effect of the evaluated drug should be objectively mea-
sureable in terms of behavior, and it should measure
something that is valuable and noticeable for a patient,
and cannot be measured otherwise. Also, the drug that is
evaluated should have an effect that is also clinically rele-
vant. Again, Duchenne Muscular Dystrophy may serve as
an example. A potential drug should do more than just
improve for instance the dystrophin values in muscle
biopsies. It should be able to improve something that is
valuable for the patient, which can be measured by activ-
ities that patients perceive as important, such as brushing
teeth or using a computer. GAS may be a useful outcome
measure, since it can evaluate a potential drug on a patient
level, and is therefore intrinsically clinically relevant.
According to guidelines on Patient Reported Out-
comes and Health Related Quality of Life by the FDA
and EMA, and open comments on these guidelines by
experts [48], the following qualities were essential: a
PRO should be based on a clearly defined framework,
patients should be involved in the development of the
measurement instrument, PRO claims should be based
on and supported by improvement in all domains of a
specific disease, an appropriate recall period is necessary
when the effects of an intervention are tested, the test-
retest reliability should be assessed, as well as the ability
to detect change and the interpretability of the measure-
ment instrument. Finally, an effect found by a PRO
measurement instrument can only be valid when found
in an RCT.
In general these requirements also apply to GAS, e.g.
patient involvement. However, not all of them are ap-
plicable to this instrument, such as test-retest reliability.
Before GAS can be used in drug trials, more validity re-
search is needed. GAS has not yet been sufficiently vali-
dated to be supported by the regulatory agencies, but it
may have potential in specific drug trials, especially in
rare diseases where there is a lack of validated and
responsive outcome measurement instruments.
Conclusion
We conclude that currently there is insufficient informa-
tion to assess the validity of GAS, due to the poor qual-
ity of the validity studies. However, the overall reported
good responsiveness of GAS suggests that it may be a
valuable measurement instrument. GAS is an outcome
measure that is inherently relevant for patients, making
it a valuable tool for research in heterogeneous and
small samples. Therefore, we think that GAS needs fur-
ther validation in drug studies, especially since GAS can
be a potential solution when only a small heterogeneous
patient group is available to test a promising new drug.
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